EP2133095A1 — Pharmaceutical composition

USPTO Abstract

The present invention provides a pharmaceutical composition comprising a combination of an Flt-3 inhibitor and at least one compound, the said pharmaceutical composition wherein an Flt-3 inhibitor is an indazole derivative represented by Formula (I) (wherein R 1 represents suctituted or unsubstituted aryl, or the like) or a pharmaceutically acceptable salt thereof, the said pharmaceutical composition wherein an Flt-3 inhibitor is a pyrimidine derivative represented by Formula (II) [wherein -X-Y-Z- represents -O-CR 17 =N- (wherein R 17 represents a hydrogen atom, lower alkyl, or the like), R 15 represents -NR 22a R 22b (wherein R 22a and R 22b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), and R 16 represents -NR 24a R 24b (wherein R 24a and R 24b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like] or a pharmaceutically acceptable salt thereof, or the like.